Form 4 for UPXI UPEXI, INC.
Accepted 2025-04-25 00:00:00 ET · period of report 2025-01-17 · accession 0001477932-25-002979 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-25 | 2025-04-17 | UPXI | Salkind Gene | Dir, 10% | P - Purchase | $2.28 | +241.2K | 365.1K | +195% | +$550.0K |
| DM | 2025-04-25 | 2025-01-17+ | UPXI | Salkind Gene | Dir, 10% | A - Grant | $0.00 | +60.0K | 25.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-17 | P | A | 241,229 | $2.28 | 365,127 | D | — | — | (F1) The Reporting Person purchased these shares in a PIPE offering conducted by the Issuer. The shares are restricted securities subject to transfer restrictions under Rule 144 of the Securities Act until such time that they are registered pursuant to a registration statement or become eligible for resale otherwise. |
| 2 | Derivative | Options to buy common stock | 2025-04-17 | A | A | 35,000 | $0.00 | 35,000 | D | $2.28 · — to 2035-04-17 | 35,000 Common | (F2) 100% of the options vest on April 17, 2026. |
| 3 | Derivative | Options to buy common stock | 2025-01-17 | A | A | 25,000 | $0.00 | 25,000 | D | $3.46 · 2025-04-17 to 2035-01-17 | 25,000 Common |